Kalaris shares additional Phase 1a data for AMD treatment TH103
- Kalaris Therapeutics Inc. (NASDAQ:KLRS) presented additional data today from its Phase 1a single ascending dose trial of TH103 for neovascular age-related macular degeneration, according to a press release statement.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
- Kalaris Therapeutics Inc. (NASDAQ:KLRS) presented additional data today from its Phase 1a single ascending dose trial of TH103 for neovascular age-related macular degeneration, according to a press release statement. The expanded dataset includes 17 treatment-naive patients and three treatment-experienced patients who completed six months of follow-up. Joel Pearlman presented the results at the American Society of Retina Specialists Annual Meeting.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- - Kalaris Therapeutics Inc. (NASDAQ:KLRS) presented additional data today from its Phase 1a single ascending dose trial of TH103 for neovascular age-related macular degeneration, according to a press release statement.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 7m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Kalaris shares additional Phase 1a data for AMD treatment TH103
Sources1TypeCoverageInvesting.com · Company News